However, the median overall survival (OS) has recently been increasing in patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma and brain metastases due to the introduction of targeted therapy [5]. The gene discussed is EGFR; the disease is lung adenocarcinoma.